The U.S. Food and Drug Administration (FDA) announced a pilot program offering Commissioner’s National Priority Vouchers (CNPVs) that enable certain drugs addressing national health priorities to receive accelerated review within one to two months, significantly faster than the standard 10 to 12 months. FDA Commissioner Martin Makary emphasized the agency’s commitment to modernizing the drug approval process amid increasing global competition. The program allows companies to submit manufacturing and prescribing information ahead of final clinical data for streamlined evaluation and aims to expedite treatments that target health crises, innovative cures, unmet needs, or bolster domestic drug manufacturing. This initiative is a strategic shift to enhance regulatory efficiency for critical therapeutics.